Treatment selection for metastatic kidney cancer based on gene expression

The discovery of a reliable biomarker for metastatic renal cell carcinoma (RCC) to predict response to treatment has been difficult to identify. This study was presented at the European Society of Medical Oncology (ESMO) Virtual Congress in September this year. The interview started by describing the currently used scoring systems used to categorise patients into […]

read more

Biomarkers for avelumab plus axitinib in advanced kidney cancer

The discovery of a reliable biomarker for how patients with advanced renal cell carcinoma (RCC) will respond to treatment has been very difficult to find. In this study, baseline samples from RCC tumours from patients in the phase III JAVELIN Renal 101 trial were analysed. The study showed that neither the presences of a biomarker […]

read more

ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

In a paper presented at this year’s European Society of Medical Oncology (ESMO) 2020 virtual congress, Dr Zeynep Zengin from City of Hope Hospital, Los Angeles, USA presented the results of a study using a commercially available circulating tumour DNA (ctDNA) assay. Assessment of ctDNA is a non-invasive method to assess genetic alterations in tumours. […]

read more

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

PBRM1 as a biomarker for kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Centre in Texas, USA, talks about the use of PBRM1 as a potential biomarker for immune response to checkpoint inhibitors. The data for this biomarker is controversial and complicated and in the future researchers need to better understand how this relates to treatment response. […]

read more

GRANT score for predicting disease-free survival in kidney cancer

In this retrospective study conducted at various hospitals in Italy, the GRANT (GRade, Age, Nodes, and Tumour) and the UISS (University of California Los Angeles Integrated Staging System) scores were compared in 134 patients with renal cell carcinoma (RCC) who had a nephrectomy. These scores are used to predict outcomes in patients with localised RCC. […]

read more

Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

read more

Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer

In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]

read more

Neutophil-to-platelet volume ratio as a predictor of outcomes for kidney cancer patients

A recent study published in the Archives of Medical Science investigated whether neutrophil-to-mean platelet volume ratio (a blood test) was able to predict overall and cancer-specific survival in patients who had a nephrectomy for localised clear cell renal cell carcinoma (RCC). Three hundred and forty-four (344) patients who had a partial or radical nephrectomy for […]

read more

Platelet-to-lymphocyte ratio predicts survival outcomes in kidney cancer

In this study, the researchers looked at the association between a high platelet-to-lymphocyte ratio in the blood and the prognosis of patients with metastatic renal cell carcinoma (RCC). Data from 1,505 patients with metastatic RCC were retrospectively analysed. There were 921 patients with a high platelet-to-lymphocyte ratio and and 584 patients with a low ratio. […]

read more
Showing 1 to 10 of 75 results
  TOP